US2009076248A1PendingUtilityA1

Plus end-directed microtubule motor required for chromosome congression

58
Assignee: UNIV CALIFORNIAPriority: Sep 11, 1997Filed: Aug 22, 2007Published: Mar 19, 2009
Est. expirySep 11, 2017(expired)· nominal 20-yr term from priority
Inventors:Kenneth W. WoodRoman SakowiczLawrence S. B. GoldsteinDon W. Cleveland
G01N 33/5008C07K 14/463C07K 16/18G01N 33/5011G01N 33/68G01N 33/6875G01N 2333/4712Y10S435/975
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides isolated nucleic acid and amino acid sequences of Xenopus CENP-E (XCENP-E), antibodies to XCENP-E, methods of screening for CENP-E modulators using biologically active CENP-E, and kits for screening for CENP-E modulators.

Claims

exact text as granted — not AI-modified
1 - 42 . (canceled) 
     
     
         43 . An antibody which specifically binds to an isolated biologically active centromere binding protein E (CENP-E), wherein the CENP-E (i) has plus end-directed microtubule motor activity, and (ii) comprises an amino acid sequence having at least 80% sequence identity with amino acid residues 1-324 of SEQ ID NO: 1. 
     
     
         44 . The antibody according to  claim 43 , wherein the antibody is a polyclonal antibody. 
     
     
         45 . The antibody according to  claim 43 , wherein the antibody is a monoclonal antibody. 
     
     
         46 . The antibody according to  claim 43 , wherein the antibody is humanized. 
     
     
         47 . The antibody according to  claim 43 , wherein the antibody is a chimeric antibody. 
     
     
         48 . The antibody according to  claim 43 , wherein the antibody is labeled. 
     
     
         49 . The antibody according to  claim 43 , wherein the antibody inhibits at least one CENP-E activity upon binding to CENP-E. 
     
     
         50 . The antibody according to  claim 49 , wherein the at least one CENP-E activity is plus end-directed microtubule motor activity. 
     
     
         51 . The antibody according to  claim 49 , wherein the at least one CENP-E activity is ATPase activity. 
     
     
         52 . The antibody according to  claim 49 , wherein the at least one CENP-E activity is microtubule binding activity. 
     
     
         53 . An antibody which specifically binds to an isolated polypeptide consisting of SEQ ID NO: 1. 
     
     
         54 . The antibody according to  claim 53 , wherein the antibody is a polyclonal antibody. 
     
     
         55 . The antibody according to  claim 53 , wherein the antibody is a monoclonal antibody. 
     
     
         56 . The antibody according to  claim 53 , wherein the antibody is humanized. 
     
     
         57 . The antibody according to  claim 53 , wherein the antibody is a chimeric antibody. 
     
     
         58 . The antibody according to  claim 53 , wherein the antibody is labeled. 
     
     
         59 . The antibody according to  claim 53 , wherein the antibody inhibits at least one CENP-E activity upon binding to CENP-E. 
     
     
         60 . The antibody according to  claim 59 , wherein the at least one CENP-E activity is plus end-directed microtubule motor activity. 
     
     
         61 . The antibody according to  claim 59 , wherein the at least one CENP-E activity is ATPase activity. 
     
     
         62 . The antibody according to  claim 59 , wherein the at least one CENP-E activity is microtubule binding activity. 
     
     
         63 . An antibody which specifically binds to a polypeptide domain consisting of amino acids 826-1106 of SEQ ID NO: 1. 
     
     
         64 . The antibody according to  claim 63 , wherein the antibody is a polyclonal antibody. 
     
     
         65 . The antibody according to  claim 63 , wherein the antibody is a monoclonal antibody. 
     
     
         66 . The antibody according to  claim 63 , wherein the antibody is humanized. 
     
     
         67 . The antibody according to  claim 63 , wherein the antibody is a chimeric antibody. 
     
     
         68 . The antibody according to  claim 63 , wherein the antibody is labeled. 
     
     
         69 . An antibody which specifically binds to a polypeptide domain consisting of amino acids 826-1106 of SEQ ID NO: 1. 
     
     
         70 . The antibody according to  claim 69 , wherein the antibody is a polyclonal antibody. 
     
     
         71 . The antibody according to  claim 69 , wherein the antibody is a monoclonal antibody. 
     
     
         72 . The antibody according to  claim 69 , wherein the antibody is humanized. 
     
     
         73 . The antibody according to  claim 69 , wherein the antibody is a chimeric antibody. 
     
     
         74 . The antibody according to  claim 69 , wherein the antibody is labeled.

Join the waitlist — get patent alerts

Track US2009076248A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.